Core Viewpoint - Hongyuan Pharmaceutical (301246) is expanding its production capacity in lithium hexafluorophosphate, indicating growth in the new energy materials sector [1] Group 1: Production Capacity - The company has an existing production capacity of 10,000 tons per year [1] - The ongoing project in Luotian aims to expand the high-purity lithium hexafluorophosphate capacity by an additional 6,000 tons per year [1] - Hubei Zhonglan Hongyuan New Energy Materials Co., in which the company holds a 41% stake, has also achieved a production capacity of 6,000 tons per year [1]

| 保荐机构名称：国联民生证券承销保荐有限公司 | 被保荐公司简称：宏源药业 | | --- | --- | | 保荐代表人：谢广化 | 联系电话：010-85127999 | | 保荐代表人：肖继明 | 联系电话：010-85127999 | | 现场检查人员：肖继明、谢广化、范一平 | | | 现场检查对应期间：2025 年度 | | | 年 月 年 月 日 现场检查时间：2025 11 26 日-2025 11 28 | | | 一、现场检查事项 | 现场检查意见 | | （一）公司治理 | 是 否 不适用 | | 现场检查手段：查阅、复制、检查、访谈 | | | 1.公司章程和公司治理制度是否完备、合规 | √ | | 2.公司章程和三会规则是否得到有效执行 | √ | | 3.三会会议记录是否完整，时间、地点、出席人员及会议 | √ | | 内容等要件是否齐备，会议资料是否保存完整 | | | 4.三会会议决议是否由出席会议的相关人员签名确认 | √ | | 5.公司董监高是否按照有关法律、行政法规、部门规章、 | √ | | 规范性文件和本所相关业务规则履行职责 | | | 6.公司董监高如发生重 ...

国联民生证券承销保荐有限公司 关于湖北省宏源药业科技股份有限公司 2025 年度持续督导培训情况的报告 三、培训效果 保荐机构认为，通过本次培训，上述人员对股东及董事和高级管理人员减持 和交易、上市公司治理、募集资金使用和管理等相关规定和监管要求有了更深刻 的认识和了解，进一步增强了公司相关人员对上市公司的规范运作意识。本次培 训达到了预期的效果。 （以下无正文） 1 （此页无正文，为《国联民生证券承销保荐有限公司关于湖北省宏源药业科技股 份有限公司 2025 年度持续督导培训情况的报告》之签章页） 根据《证券发行上市保荐业务管理办法》《深圳证券交易所上市公司自律监 管指引第 13 号——保荐业务》等有关规定的要求，作为湖北省宏源药业科技股 份有限公司（以下简称"宏源药业"或"公司"）首次公开发行股票并在创业板 上市后进行持续督导的保荐机构，国联民生证券承销保荐有限公司（以下简称"保 荐机构"）于 2025 年 11 月 27 日对宏源药业实际控制人、控股股东、董事、高级 管理人员及其他相关人员进行了 2025 年度持续督导现场培训，对于未现场参与 培训的人员采用了发送培训课件、视频会议的方式进行培训。 一、 ...

Core Viewpoint - Hongyuan Pharmaceutical's executives indicated that some of their pre-IPO restricted shares will become tradable on September 20, 2024, following the expiration of the lock-up period [2]. Summary by Relevant Sections - **Executive Shareholding**: The company stated that during the tenure of the executives, 25% of their total shareholdings will be unlocked annually, while the remaining 75% will remain locked automatically [2].

Group 1 - The core issue raised by investors pertains to the significant difference between the beginning and ending balances of the construction in progress for the Luotian hexafluorophosphate sodium project in the 2025 semi-annual report [2] - The company clarified that the decrease in the balance is primarily due to part of the project reaching the intended usable state, leading to its reclassification from construction in progress to fixed assets in accordance with the Accounting Standards for Enterprises [2]

Group 1 - The company Hongyuan Pharmaceutical (301246) has a designed production capacity of 8,000 tons per year for lithium hexafluorophosphate products [1] - The company's market share for metronidazole raw materials is leading in the industry, with products sold to dozens of countries and regions globally [1] - The company has established good cooperative relationships with well-known pharmaceutical enterprises both domestically and internationally [1]

Core Viewpoint - Hongyuan Pharmaceutical (301246.SZ) has a designed production capacity of 8,000 tons per year for lithium hexafluorophosphate products and holds a leading market share in the active pharmaceutical ingredient metronidazole, with products sold to dozens of countries and regions globally, establishing good partnerships with well-known pharmaceutical companies both domestically and internationally [1] Group 1 - The company has a designed production capacity of 8,000 tons per year for lithium hexafluorophosphate products [1] - The company holds a leading market share in metronidazole active pharmaceutical ingredients [1] - The company's products are sold to dozens of countries and regions globally [1] Group 2 - The company has established good partnerships with well-known pharmaceutical companies [1]

Core Viewpoint - The company has a designed production capacity of 8,000 tons per year for lithium hexafluorophosphate products and holds a leading market share in the active pharmaceutical ingredient metronidazole, with products sold to dozens of countries and regions globally, establishing strong partnerships with well-known pharmaceutical companies [1] Group 1 - The company has a designed production capacity of 8,000 tons per year for lithium hexafluorophosphate products [1] - The company holds a leading market share in metronidazole active pharmaceutical ingredients [1] - The company's products are sold to dozens of countries and regions globally [1] Group 2 - The company has established strong partnerships with well-known pharmaceutical companies [1]

Group 1 - The company, Hongyuan Pharmaceutical (301246), responded to investor inquiries on November 19, indicating that details regarding product production and planning should be monitored through the company's information disclosures [1]

Core Points - The company announced the construction project of the Wuxue Hongyuan plant, which includes public utilities and auxiliary production facilities [1] - The budget for the Wuxue Hongyuan plant supporting project is 138 million yuan, with actual investment reaching the same amount by the mid-2025 report, indicating a project progress of 99.95% [3] - The expected completion date for the project is September 18, 2025 [3] Summary by Categories - **Project Details** - The main construction content of the Wuxue Hongyuan plant supporting project includes public utilities and auxiliary production facilities [1] - **Financials** - The project has a budget of 138 million yuan, with actual expenditures matching this budget as of the mid-2025 report [3] - **Progress and Timeline** - The project is nearly complete, with a progress rate of 99.95%, and is expected to be finished by September 18, 2025 [3]